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E-mail address: numakawa@ncnp.go.jp (T. NumakIncreased glucocorticoids (GCs) have been implicated in the pathophysiology of depressive disor-
der. We previously found that dexamethasone (DEX, a synthetic GC) repressed brain-derived neu-
rotrophic factor (BDNF)-induced synaptic proteins via suppressing extracellular signal-regulated
protein kinase (ERK) signaling. Here, we investigated the possible involvement of Src homol-
ogy-2 domain-containing phosphatase2 (Shp2), an ERK signaling mediator. We found that DEX
suppressed Shp2 interaction with TrkB, a receptor for BDNF, in cultured cortical neurons.
NSC87877, a Shp2 inhibitor, mimicked DEX, and Shp2 overexpression reversed the effect of
DEX, suggesting that GCs suppress ERK signaling through inhibiting the interaction of Shp2 with
TrkB.
Structured summary of protein interactions:
TrkB physically interacts with Shp2 by anti bait coimmunoprecipitation (View interaction)
FRS2 physically interacts with Shp2 by anti bait coimmunoprecipitation (View interaction)
Grb2 physically interacts with Shp2 by anti bait coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Sustained elevation of serum GCs have been implicated in the
pathophysiology of depressive disorder [1]. We previously showed
that DEX inhibited BDNF-induced synaptic proteins via inhibiting
the activation of mitogen-activated protein kinase (MAPK/ERK)
pathway in developing hippocampal neurons [2]. Activation of
receptor tyrosine kinases (RTKs), including TrkB, triggers the
kinase cascade of RAS, c-Raf, MEK, and ERK1/2, resulting in the
modulation of transcription of various genes [3,4]. Importantly,
we showed that long-lasting ERK1/2 activation is essential for
BDNF-dependent upregulation of synaptic proteins including glu-
tamate receptors [2]. However, detailed mechanisms underlying
the negative inﬂuence of DEX on BDNF-induced synaptic proteins
have not been elucidated.
BDNF has roles in neuronal survival and synaptic plasticity via
activation of intracellular signaling pathways, including phosphati-
dylinositol 3-kinase (PI3K), phospholipase Cc (PLCc), and MAPK
pathways [4,5]. Activation of these pathways requires interactionchemical Societies. Published by E
Disorder Research, National
ology and Psychiatry, 4-1-1
: +81 42 346 1744.
awa).of various proteins with TrkB. In MAPK activation, binding of
growth factor receptor-bound protein 2/son of sevenless (Grb2/
SOS) complex is necessary for Ras activation [5,6], and the recruit-
ment of Grb2/Shp2 complex is involved in the maintenance of
ERK1/2 activation [7]. Indeed, downregulation of Shp2 by speciﬁc
siRNA inhibits ERK1/2 activation by epidermal growth factor
(EGF) in HEK293 cells [8]. Transfection of Shp2 mutant lacking
the phosphatase domain, decreased ERK1/2 activation [9]. Shp2 is
one of the causal genes of Noonan syndrome that is caused by
mutations of various MAPK pathway-related genes [10]. Changes
in ERK1/2 signaling are also suggested to be involved in psychiatric
disorders [11]. Therefore, a functional relationship between Shp2
and GCs is interesting.
Here, we investigated the possible involvement of Shp2 in sup-
pressed ERK1/2 activation after exposure to GC. We found that
BDNF-induced interaction of Shp2 with TrkB was diminished by
DEX.
2. Materials and method
2.1. Chemicals
DEX was dissolved in dimethyl sulfoxide (DMSO, Wako Pure
Chemical Industries, Ltd., Osaka, Japan). DMSO alone had no effectlsevier B.V. All rights reserved.
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obtained from SIGMA (MO, USA). Regeneron Pharmaceutical Co.,
Takeda Chemical Industries, Ltd., and Sumitomo Co. Ltd. donated
BDNF.
2.2. Cortical cultures
Cortical neurons were prepared from postnatal 2 day-old rats
(SLC, Shizuoka, Japan) as reported previously [12]. Cultured neu-
rons were treated with 0.01–10 lM of DEX at 4 days in vitro
(DIV4), and 24 h later, BDNF was applied at 100 ng/ml. NSC
(10 lM) was applied 10 min before BDNF addition. All animals
were treated according to the institutional guideline for care and
use of animals.
2.3. Western blot and immunoprecipitation
Western blot were performed as reported [2]. The protein con-
centration of cell lysate was quantiﬁed, and the same amount of
total protein was assayed for each blotting. Immunoprecipitation
was conducted as shown previously [13]. Anti-NR2A, anti-synapsin
I, anti-TUJ1 (class III b-tubulin), anti-phospho-ERK, and anti-ERK
antibodies were used as reported previously [2]. Anti-Shp2 (BD
Transduction Laboratories, NJ, USA), and anti-Gab1 antibodies
(Millipore, MA, USA) were used at 1:1000 dilution. Anti-phospho-
Shp2 (1:1000) and anti-phospho-TrkA (1:1000) antibodies were
obtained from Cell Signaling Technology (MA, USA). Anti-Grb2
(1:1000) antibody, and Anti-FRS2 antibody were from Santa Cruz
Biotechnology Inc. (CA, USA). Immunoreactivity was quantiﬁed
with Lane & Spot Analyzer software (ATTO Corporation, Tokyo,
Japan).
2.4. Overexpression
Sindbis-virus for Shp2 overexpression was constructed as re-
ported previously [13]. The virus produces arbitrary protein and
GFP independently in the infected cell. To construct the pSi-
nEGdsp-Shp2 viral plasmid, cDNA of SH-SY5Y cell were obtainedFig. 1. Expression/phosphorylation of Shp2 after BDNF application with or without DEX p
was treated at DIV5. (A) Shp2 expression 48 h after BDNF treatment was unchanged by D
Trk (pTrk) after BDNF application. (C) DEX (0.01–10 lM) did not inﬂuence pShp2 and
Quantiﬁcation of pTrk, and pShp2. Data represent mean ± S.D. (n = 4). #P < 0.05 versus Nby reverse transcript from total RNA using RNeasy Plus Mini Kit
(Qiagen) and SuperscriptIII (Invitrogen). Shp2 cDNA was ampliﬁed
by PCR with KOD-polymerase (Toyobo, Osaka) and speciﬁc primers
(forward 50-AAAACGCGTATGACATCGCGGAGAT-30 and reverse 50-
CCCCACGTGTCATCTGAAACTTTTC-30). The ampliﬁed fragments
were cleaved with MluI and PmlI, and then inserted at each restric-
tion enzyme sites of the pSinEGdsp. The insert sequence was con-
ﬁrmed that it was human Shp2 (Accession Number; NM002834).
Shp2 protein expression in Shp2-infected cultures was 2.8 ± 2.6
(n = 4) times higher than control virus (GFP only).
2.5. Statistical analysis
Data were expressed as mean ± standard deviation (S.D.). Statis-
tical signiﬁcance was evaluated by Mann–Whitney U (MWU) test
after conducting Kruskal–Wallis (KW) test.
3. Results
3.1. DEX had no effect on expression and phosphorylation of Shp2
Initially, we examined the effect of DEX on the level of Shp2.
Cultured cortical neurons (DIV4) was pretreated with DEX for
24 h, and then BDNF was applied for 48 h. Endogenous Shp2
expression was unchanged by DEX and/or BDNF (Fig. 1A). Next,
we examined Shp2 phosphorylation (pShp2). At 1 min after BDNF
addition, signiﬁcant phosphorylation of Trks (pTrks) was observed,
however, pShp2 remained weak. Five to 10 min later, pShp2
reached the maximum level, and gradually decreased within
30 min (Fig. 1B). As shown in Fig. 1C, D, pShp2 and pTrks after
10 min-BDNF treatment were not inﬂuenced by DEX.
3.2. DEX attenuated Shp2 interaction with Trk
As assembly of cytosolic proteins to RTKs is important for intra-
cellular signalings, Shp2–Trk interaction was examined. After
immunoprecipitation of Trk, co-precipitated Shp2 was detected
10 min after BDNF stimulation (Fig. 2Aa, b). DEX inhibited theretreatment. DEX (1 lM) was applied to cortical neurons at DIV4. BDNF (100 ng/ml)
EX. TUJ1 is a control. (B) Time-course of phosphorylation of Shp2 (pShp2) and that of
pTrk. Each phosphorylation 10 min after BDNF application was determined. (D)
one.
Fig. 2. Interaction between Shp2 and Trk was decreased by DEX. (A) (a) Time-course analysis of co-precipitated Shp2 after immunoprecipitation with anti-Trk antibody. DEX
(1 lM) inhibited the Shp2–Trk interaction detected 10 min after BDNF (100 ng/ml) application. (b) Quantiﬁcation of co-precipitated Shp2. The mean values were obtained
from two independent cultures. (B) Shp2–Trk interaction after BDNF treatment for 10 min with or without DEX pretreatment (C) Dose-dependent inhibitory effect of DEX
(0.01–10 lM) on the Shp2–Trk interaction. Data represent mean ± S.D. (n = 4). #P < 0.05 versus None, ⁄P < 0.05 versus sole BDNF.
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interaction 10 min after BDNF addition was signiﬁcant (Fig. 2B)
and dose-dependent (Fig. 2C). The inhibitory effect of DEX was also
observed in maturated neurons (DIV13), although BDNF-induced
Shp2–Trk interaction was weak (Supplementary Fig. 1).
3.3. Shp2 inhibitor mimicked DEX
We examined the effect of NSC which inhibits activities of Shp2
and MAPK [14]. As expected, both DEX and NSC suppressed the
pERK1/2 after 6 h-BDNF treatment (Fig. 3A). Importantly, co-treat-
ment of NSC with DEX had no additional or synergistic effect com-
pared with sole application (Fig. 3A and B). In our previous studies,
acute activation of ERK1/2 (within 10 min after BDNF addition)
was unchanged, but activated ERK1/2 after 6 h-BDNF treatment
was decreased by DEX [2,13]. Here, we examined the pERK1/2 after
6 h-BDNF stimulation. Consistent with our previous results [2],
BDNF increased NR2A (one of glutamate receptors) (Fig. 3C).
Though DEX suppressed the NR2A upregulation, any additional
or synergistic effect was not caused by co-application with NSC(Fig. 3C and D). NR2A levels after sole DEX treatment was not
changed (0.85 ± 0.27 (n = 4), ratio value versus control). BDNF-in-
duced synapsin I, one of presynaptic proteins, was also suppressed
by DEX and NSC, although additional suppression was not found by
co-application (Fig. 3C). To check contribution of astrocytes in our
cultures, levels of pERK1/2 or pAkt (one of Trk downstream mole-
cules) after BDNF stimulation was determined with or without ara-
binosylcytosine (AraC, a proliferation inhibitor) treatment, and no
alteration by AraC was conﬁrmed (Supplementary Fig. 2). In pure
astroglial cultures, pERK1/2 and pAkt were induced by EGF, but
not by BDNF, suggesting that the observed effects of BDNF in this
study were neuronal responses.
3.4. Shp2 overexpression reversed the inhibitory effect of DEX on NR2A
levels
If decrease of the Shp2–TrkB interaction is critical for DEX-
decreased NR2A levels, overexpression of Shp2 would repress the
inhibitory action of DEX. Shp2 overexpression rescued the inhibi-
tory action of DEX on NR2A upregulation by BDNF (Fig. 4). Further-
Fig. 3. BDNF-increased pERK1/2 and synaptic protein were suppressed by Shp2 inhibitor, NSC87877 (NSC). (A) Inhibitory effect of NSC or DEX on the pERK1/2. BDNF was
applied for 6 h. (B) Quantiﬁcation of pERK1/2. (C) Levels of NR2A and synapsin I of 48 h-BDNF application. (D) Quantiﬁcation of NR2A levels. Data represent mean ± S.D.
(n = 4). #P < 0.05 versus None, ⁄P < 0.05 versus sole BDNF.
Fig. 4. Shp2 overexpression rescued the suppressed expression of NR2A by DEX.
Neurons at DIV4 were infected with Shp2- or vehicle-virus, and the expression of
Shp2, NR2A, and TUJ1 were examined at DIV7. Neurons were exposed to DEX
(1 lM) from DIV4, and BDNF (100 ng/ml) was added at DIV5.
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(Grb2-associated binder 1) after DEX treatment, and they were
not changed (Supplementary Fig. 3A). Shp2 interactions with
Grb2 or FRS2 (ﬁbroblast growth factor receptor substrate 2) were
not inﬂuenced by DEX (Supplementary Fig. 3B). Shp2–Gab1 inter-
action was not found (Supplementary Fig. 3B).
4. Discussion
We found that DEX suppressed activation of ERK1/2 possibly
through inhibiting the interaction of Shp2 with TrkB. The duration
of MAPK activation and combination with other signaling cascades
are important for cellular functions including synaptic plasticity.
BDNF induces relatively long-lasting activation of MAPK pathway
[9], and we reported the importance of such sustained activation
of ERK1/2 for BDNF-potentiated synaptic maturation [2]. In the
pathophysiology of psychiatric disorders, change in BDNF/TrkB
system including association with GC exposure is a focus of inter-
est [15,16]. In our system, DEX suppressed BDNF-stimulated ERK1/
2 without inﬂuencing Trk activation. Thus, alteration of down-
stream signalings should also be determined in further investiga-
tions on steroid hormones’ action.
In this study, we used anti-phospho-TrkA (Tyr490) antibody, as
it recognizes the corresponding residue of pTrkB and phosphoryla-
tion of Tyr490 is required for MAPK activation [17]. Since BDNF and
neurotrophin-4/5 (speciﬁc ligands for TrkB) had a strong effect onTrks phosphorylation in our cultures [12], the observed pTrk was
assumed to be pTrkB.
A negative feedback system regulates MAPK pathway. MKP-1
(MAPK phosphatase-1) increases after stimulation of MAPK signal-
ing, in turn, MKP-1 prohibits the MAPK activation [18]. In contrast,
Shp2 positively maintains the state of MAPK activation [6]. In the
present study, we observed that DEX inhibited the BDNF-depen-
dent Shp2–TrkB interaction. The interaction may be indirect,
because it is known that Shp2 binds to Gab1, Gab1 binds to
Grb2, and Grb2 binds to RTKs [6,19,20]. Shp2 associates with
FRS2 which binds to TrkB [9,21]. Shp2 is included in the TrkB-
immunoprecipitated complex in cultured cerebellar neurons [22].
In our cultures, endogenous Grb2 and Gab1 were unchanged by
DEX. Shp2 interaction with Grb2, Gab1 or FRS2 was not inﬂuenced
by DEX. Further studies are needed to determine possible contribu-
tion of these molecules in the Shp2–TrkB interaction.
It seems odd that DEX inﬂuences on the Shp2–TrkB interaction
but not on Shp2 phosphorylation. Although activation of RTK trig-
gers Shp2 phosphorylation, it is unknown that the binding of Shp2
to RTK is essential for the phosphorylation. It is possible that Shp2
becomes unbound from TrkB complex after interaction and phos-
phorylation of Shp2, even if Shp2–TrkB interaction precedes the
Shp2 phosphorylation. Sprouty, an inhibitor protein for MAPK
pathway, is also phosphorylated by RTK activation at similar
time-course with Shp2, and inhibits the interaction of Shp2–Grb2
[7]. Interestingly, Shp2 dephosphorylates sprouty, which decreases
the recruitment of sprouty to Grb2, resulting in prolonged activa-
tion of the MAPK pathway [7]. Therefore, Shp2 and sprouty are
suggested to determine the duration and robustness of MAPK acti-
vation [6,7]. Although it remained unclear whether DEX changes
sprouty expression and function, DEX may inﬂuence on sprouty-
like protein that mediates Shp2 interaction with TrkB.
Increased GCs and downregulation of BDNF actions have been
implicated in the pathophysiology of depressive disorder [1]. We
recently reported that DEX reduces TrkB–PLCc interaction, which
is essential for neurotransmitter release elicited by BDNF [13].
Furthermore, we showed that DEX inhibits BDNF-increased synap-
tic proteins via repressing the ERK1/2 activation [2]. Here, we dem-
onstrate that the reduction in the Shp2–TrkB interaction after DEX
3228 E. Kumamaru et al. / FEBS Letters 585 (2011) 3224–3228exposure results in ERK1/2 inhibition. These ﬁndings indicate that
GCs have negative impact on BDNF-mediated neuronal functions
via several mechanisms, which may be related with the patho-
physiology of depressive disorder.
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